已收录 268920 条政策
 政策提纲
  • 暂无提纲
A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease
[摘要] The cognitive performance of 55 non-demented idiopathic Parkinson's disease (PD) patients treated with levodopa alone or receiving dopamine agonist pramipexole as add-on therapy to levodopa was evaluated in the present study during 6 months of treatment. Neuropsychological tests were administered two times. In the first assessment to differentiate test sensitive to cognitive changes typical for PD control group was also assessed. After 6 months of treatment PD patients were retested only with tests that differentiate them from control group. Compared to controls PD patients showed inferior performance on Stroop Interference test, Trail Making test, letter fluency and Hooper Visual Organization Test. No statistically significant differences between two groups and first and second neuropsychological assessment were found. Present findings indicate that pramipexole as add-on therapy to levodopa is safe in non-demented PD patients in terms of the effect on cognitive performance. (C) 2006 Elsevier B.V. All rights reserved.
[发布日期] 2006-10-25 [发布机构] 
[效力级别]  Proceedings Paper [学科分类] 
[关键词] Parkinson's disease;cognition;dopamine agonists;pramipexole;levodopa;executive function [时效性] 
   浏览次数:3      统一登录查看全文      激活码登录查看全文